• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制心营养素 1 的过表达参与了梓醇的抗纤维化作用。

Inhibition of cardiotrophin‑1 overexpression is involved in the anti‑fibrotic effect of Astrogaloside IV.

机构信息

Department of Physiology, Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China.

Department of Pharmacology, Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China.

出版信息

Mol Med Rep. 2017 Dec;16(6):8365-8370. doi: 10.3892/mmr.2017.7676. Epub 2017 Sep 29.

DOI:10.3892/mmr.2017.7676
PMID:28990065
Abstract

Astragaloside IV (AsIV), one of the major active ingredients in Astragalus membranaceus, has demonstrated remarkable antifibrotic effects via its antioxidative activity. Cardiac fibrosis is an important pathological mechanism during cardiac remodelling associated with heart failure. In the present study, the mechanism underlying the antifibrotic effect of AsIV upon isoprenaline (ISO) stimulation was investigated. AsIV significantly improved cardiac fibrosis in vivo and dose‑dependently inhibited ISO‑induced CF proliferation in vitro. The ISO‑triggered elevation in reactive oxygen species (ROS) levels was remarkably inhibited by AsIV, as well as ROS scavenger N‑acetylcysteine (NAC), and not affected by cardiotrophin‑1 (CT‑1) knockdown. In addition, AsIV effectively reversed ISO‑induced upregulation of CT‑1 expression, which was blunted by pretreatment with NAC. Cardiac fibroblast (CF) proliferation and collagen Ι overexpression induced by ISO stimulation were effectively abrogated by AsIV, NAC, and CT‑1 small interfering RNA transfection. Taken together, these results demonstrated that AsIV was able to effectively inhibit ISO‑induced CF proliferation and collagen production through negative regulation of ROS‑mediated CT‑1 upregulation.

摘要

黄芪甲苷(AsIV)是黄芪的主要活性成分之一,具有抗氧化活性,表现出显著的抗纤维化作用。心肌纤维化是心力衰竭相关心脏重构的重要病理机制。在本研究中,研究了 AsIV 对异丙肾上腺素(ISO)刺激的抗纤维化作用的机制。AsIV 显著改善了体内的心肌纤维化,并呈剂量依赖性抑制了体外 ISO 诱导的 CF 增殖。AsIV 显著抑制了 ISO 触发的活性氧(ROS)水平升高,以及 ROS 清除剂 N-乙酰半胱氨酸(NAC),而不影响心营养素-1(CT-1)的敲低。此外,AsIV 有效逆转了 ISO 诱导的 CT-1 表达上调,而 NAC 预处理则减弱了这种上调。AsIV、NAC 和 CT-1 小干扰 RNA 转染有效阻断了 ISO 刺激诱导的 CF 增殖和胶原Ⅰ过度表达。综上所述,这些结果表明,AsIV 通过负调控 ROS 介导的 CT-1 上调,有效抑制 ISO 诱导的 CF 增殖和胶原产生。

相似文献

1
Inhibition of cardiotrophin‑1 overexpression is involved in the anti‑fibrotic effect of Astrogaloside IV.抑制心营养素 1 的过表达参与了梓醇的抗纤维化作用。
Mol Med Rep. 2017 Dec;16(6):8365-8370. doi: 10.3892/mmr.2017.7676. Epub 2017 Sep 29.
2
Astragaloside IV inhibits isoprenaline‑induced cardiac fibrosis by targeting the reactive oxygen species/mitogen‑activated protein kinase signaling axis.黄芪甲苷IV通过靶向活性氧/丝裂原活化蛋白激酶信号轴抑制异丙肾上腺素诱导的心脏纤维化。
Mol Med Rep. 2017 Apr;15(4):1765-1770. doi: 10.3892/mmr.2017.6220. Epub 2017 Feb 17.
3
Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.黄芪甲苷IV通过调节NF-κB/PGC-1α信号介导的能量生物合成来预防异丙肾上腺素诱导的心肌肥大。
PLoS One. 2015 Mar 4;10(3):e0118759. doi: 10.1371/journal.pone.0118759. eCollection 2015.
4
Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways.黄芪甲苷通过减轻eNOS解偶联介导的氧化应激和抑制ROS-NF-κB途径来改善异丙肾上腺素诱导的血管功能障碍。
Int Immunopharmacol. 2016 Apr;33:119-27. doi: 10.1016/j.intimp.2016.02.009. Epub 2016 Feb 21.
5
Effect of astragaloside IV against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels.黄芪甲苷IV通过线粒体ATP敏感性钾通道对氧化应激诱导的大鼠心肌细胞凋亡的影响。
Mol Med Rep. 2015 Jul;12(1):371-6. doi: 10.3892/mmr.2015.3400. Epub 2015 Feb 27.
6
Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions.黄芪甲苷通过抑制高糖条件下的 NADPH 氧化酶/ROS/Akt/NF-κB 通路来防止人肾小球系膜细胞损伤。
Int J Mol Med. 2014 Jul;34(1):167-76. doi: 10.3892/ijmm.2014.1741. Epub 2014 Apr 9.
7
Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling.黄芪甲苷IV通过增强Nrf2信号通路抑制阿霉素诱导的心脏铁死亡。
Mol Cell Biochem. 2021 Jul;476(7):2603-2611. doi: 10.1007/s11010-021-04112-6. Epub 2021 Mar 3.
8
Astragaloside IV suppresses inflammatory mediator production in synoviocytes and collagen‑induced arthritic rats.黄芪甲苷IV抑制滑膜细胞和胶原诱导性关节炎大鼠中炎症介质的产生。
Mol Med Rep. 2016 Apr;13(4):3289-96. doi: 10.3892/mmr.2016.4923. Epub 2016 Feb 22.
9
Compatibility of Tanshinone IIA and Astragaloside IV in attenuating hypoxia-induced cardiomyocytes injury.丹参酮IIA与黄芪甲苷在减轻缺氧诱导的心肌细胞损伤中的配伍性
J Ethnopharmacol. 2017 May 23;204:67-76. doi: 10.1016/j.jep.2017.03.053. Epub 2017 Apr 5.
10
Astragaloside IV attenuates apoptosis of hypertrophic cardiomyocyte through inhibiting oxidative stress and calpain-1 activation.黄芪甲苷IV通过抑制氧化应激和钙蛋白酶-1激活减轻肥厚型心肌细胞的凋亡。
Environ Toxicol Pharmacol. 2015 Nov;40(3):764-73. doi: 10.1016/j.etap.2015.09.007. Epub 2015 Sep 16.

引用本文的文献

1
Pharmacological Effects of Astragaloside IV: A Review.黄芪甲苷的药理作用:综述。
Molecules. 2023 Aug 18;28(16):6118. doi: 10.3390/molecules28166118.
2
Astragaloside IV for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis.黄芪甲苷治疗心力衰竭的临床前证据和可能机制:系统评价和荟萃分析。
Chin J Integr Med. 2023 Jul;29(7):626-633. doi: 10.1007/s11655-023-3636-x. Epub 2023 May 18.
3
and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms.及其作为纤维化疾病治疗选择的配方:药理学与作用机制。
Front Pharmacol. 2022 Nov 3;13:1040350. doi: 10.3389/fphar.2022.1040350. eCollection 2022.
4
: A review of its anti-fibrosis properties.对其抗纤维化特性的综述。
Front Pharmacol. 2022 Sep 7;13:976561. doi: 10.3389/fphar.2022.976561. eCollection 2022.
5
Advances in Chemical Composition, Extraction Techniques, Analytical Methods, and Biological Activity of .《 化学成分、提取技术、分析方法和生物活性的研究进展 》
Molecules. 2022 Feb 4;27(3):1058. doi: 10.3390/molecules27031058.
6
Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases.黄芪甲苷:治疗心血管疾病的有效药物。
Drug Des Devel Ther. 2020 Sep 15;14:3731-3746. doi: 10.2147/DDDT.S272355. eCollection 2020.
7
Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism.黄芪甲苷通过改善能量代谢缓解 2 型糖尿病引起的心肌损伤。
Mol Med Rep. 2019 Nov;20(5):4612-4622. doi: 10.3892/mmr.2019.10716. Epub 2019 Oct 1.
8
A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Radix: Implications for Radix as a Personalized Medicine.基于化学成分、药理学和药代动力学的系统性综述:对个体化医疗中葛根的启示
Int J Mol Sci. 2019 Mar 22;20(6):1463. doi: 10.3390/ijms20061463.